Related Experiment Video
Updated: Aug 13, 2026

Monochrome Multiplex Quantitative PCR Telomere Length Measurement
Published on: March 22, 2024
Monocyte telomere shortening and oxidative DNA damage in type 2 diabetes
Mike J Sampson1, Mark S Winterbone, Jackie C Hughes
1Elsie Bertram Diabetes Centre, Norfolk and Norwich University Hospital National Health Service Trust, Norwich NR4 7UA, UK. mike.sampson@nnuh.nhs.uk
Objective:
Telomeres are DNA sequences necessary for DNA replication, which shorten at cell division at a rate related to levels of oxidative stress. Once shortened to a critical length, cells are triggered into replicative senescence. Type 2 diabetes is associated with oxidative DNA damage, and we hypothesized that telomere shortening would characterize type 2 diabetes.
Research Design And Methods:
We studied 21 male type 2 diabetic subjects (mean age 61.2 years, mean HbA(1c) 7.9%) selected to limit confounding effects on telomere length and 29 matched control subjects. Telomere length was measured in peripheral venous monocyte and T-cells (naïve and memory) by fluorescent in situ hybridization and oxidative DNA damage by flow cytometry of oxidized DNA bases. Peripheral insulin resistance (homeostasis model assessment) and high-sensitivity C-reactive protein (hsCRP) were measured.
Results:
Mean monocyte telomere length in the diabetic group was highly significantly lower than in control subjects (4.0 [1.1] vs. 5.5 [1.1]; P < 0.0001), without significant differences in lymphocyte telomere length. There was a trend toward increased oxidative DNA damage in all diabetes cell types examined and a significant inverse relationship between oxidative DNA damage and telomere length (r = -0.55; P = 0.018) in the diabetic group. Telomere length was unrelated to plasma CRP concentration or insulin resistance.
Conclusions:
Monocyte telomere shortening in type 2 diabetes could be due to increased oxidative DNA damage to monocyte precursors during cell division. This data suggests that monocytes adhering to vascular endothelium and entering the vessel wall in type 2 diabetes are from a population with shorter telomeres and at increased risk of replicative senescence within vascular plaque.
Insights
Type 2 diabetes is linked to shorter telomeres in monocytes, potentially due to increased oxidative DNA damage. This cellular aging may contribute to vascular complications in diabetic patients.
Area of Science:
- Cellular and Molecular Biology
- Endocrinology
- Gerontology
Background:
- Telomeres, protective DNA caps, shorten with cell division and oxidative stress.
- Replicative senescence, triggered by critically short telomeres, is a hallmark of aging.
- Type 2 diabetes is associated with increased oxidative DNA damage, suggesting a potential link to telomere attrition.
Purpose of the Study:
- To investigate whether telomere shortening characterizes type 2 diabetes.
- To explore the relationship between telomere length, oxidative DNA damage, and metabolic markers in type 2 diabetes.
Main Methods:
- Compared telomere length in monocytes and T-cells between 21 male type 2 diabetic subjects and 29 matched controls.
- Measured oxidative DNA damage using flow cytometry.
- Assessed peripheral insulin resistance and high-sensitivity C-reactive protein (hsCRP).
Main Results:
- Monocyte telomere length was significantly shorter in diabetic subjects compared to controls (P < 0.0001).
- No significant difference in lymphocyte telomere length was observed.
- A significant inverse correlation between oxidative DNA damage and telomere length was found in diabetic individuals (r = -0.55; P = 0.018).
Conclusions:
- Monocyte telomere shortening in type 2 diabetes may result from heightened oxidative DNA damage during cell division.
- Shorter telomeres in monocytes may increase the risk of replicative senescence and vascular complications in type 2 diabetes.
Related Concept Videos
Type II Diabetes I: Introduction
Type II Diabetes II: Pathophysiology
Type I Diabetes II: Pathophysiology
Diabetes Mellitus: Type 2 and Gestational
Psychoneuroimmunology: Diabetes and Cancer
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
